Transdiagnostic association between subjective insomnia and depressive symptoms in major psychiatric disorders.

In psychiatric disorders, comorbid depressive symptoms are associated with clinically important issues such as reduced quality of life, a poor prognosis, and increased suicide risk. Previous studies have found a close relationship between insomnia and depressive symptoms in major depressive disorder (MDD), and that actively improving insomnia heightens the improvement of depressive symptoms. This study aimed to investigate whether the association between insomnia and depressive symptoms is also found in other psychiatric disorders besides MDD. The subjects were 144 patients with MDD (

Informations de copyright

Copyright © 2023 Nakajima, Kaneko, Fujii, Kizuki, Saitoh, Nagao, Kawamura, Yoshiike, Kadotani, Yamada, Uchiyama, Kuriyama and Suzuki.

Déclaration de conflit d'intérêts

YK reports personal fees from Eisai, Meiji Seika Pharma, Otsuka Pharmaceutical, and Sumitomo Pharma, outside the submitted work. NF reports personal fees from Yoshitomi Pharmaceutical, outside the submitted work. JK reports personal fees from Otsuka Pharmaceutical, outside the submitted work. KS reports personal fees from Yoshitomi Pharmaceutical and Eisai, outside the submitted work. KN reports personal fees from Dainippon Sumitomo and Takeda Pharmaceutical, outside the submitted work. AK reports speaker’s honorarium from Otsuka Pharmaceutical and Takeda Pharmaceutical, outside the submitted work. TY reports personal fees from MSD and Takeda Pharmaceutical, outside the submitted work. HK received grants from the Investigator-Initiated Studies Program of Merck Sharp and Dohme LLC/MSD KK, Eisai Co., Ltd., and SECOM Science and Technology Foundation. HK reports consulting fees from Takeda Pharmaceutical Co., Ltd. HK was supported by donations from Fukuda Lifetech Co., Ltd., and Fukuda Life Tech Keiji Co., Ltd., to the Shiga University of Medical Science, outside the submitted work. NY has received speaker’s honorarium from Eisai, MSD, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Otsuka Pharmaceutical, Takeda Pharmaceutical, and Yoshitomi Pharmaceutical, outside the submitted work. MU reports consulting fees from Idorsia Pharmaceuticals Japan, Lixil Corporation, Sanofi, and Taisho Pharmaceutical, and speaker’s honorarium from Eisai, Meiji Seika Pharma, MSD, Otsuka Pharmaceutical, Sumitomo Pharma, and Takeda Pharmaceutical, outside the submitted work. KK reports research grants from Otsuka Pharmaceutical and Pfizer, research grants and speaker’s honorarium from Eisai, MSD, and Takeda Pharmaceutical, and speaker’s honorarium from Yoshitomi Pharmaceutical and Sumitomo Pharma, outside the submitted work. MS has received research grants from Mochida Pharmaceutical and Shionogi Pharma, research grants and speaker’s honorarium from EA Pharma, Eisai, Otsuka Pharmaceutical, Sumitomo Pharma, and Takeda Pharmaceutical, and speaker’s honorarium from Meiji Seika Pharma, MSD, Viatris, and Yoshitomi Pharmaceutical, and payment for expert testimony from Mochida Pharmaceutical, outside the submitted work. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.